Actoplus Met is a drug owned by Takeda Pharmaceuticals Usa Inc. It is protected by 6 US drug patents filed from 2013 to 2016. Out of these, 2 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 03, 2029. Details of Actoplus Met's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9320714 | Tablet |
Feb, 2029
(3 years from now) | Active |
| US9101660 | Solid preparation |
Jan, 2027
(1 year, 8 months from now) | Active |
| US6166042 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6172090 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US5965584 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
| US6166043 | Pharmaceutical composition |
Jun, 2016
(8 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Actoplus Met's patents.
Latest Legal Activities on Actoplus Met's Patents
Given below is the list of recent legal activities going on the following patents of Actoplus Met.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jan, 2023 | US9101660 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Jan, 2019 | US9101660 |
| Post Issue Communication - Certificate of Correction | 29 Jan, 2016 | US9101660 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Aug, 2015 | US9101660 |
| Recordation of Patent Grant Mailed Critical | 11 Aug, 2015 | US9101660 |
| Email Notification Critical | 23 Jul, 2015 | US9101660 |
| Issue Notification Mailed Critical | 22 Jul, 2015 | US9101660 |
| Dispatch to FDC | 07 Jul, 2015 | US9101660 |
| Application Is Considered Ready for Issue Critical | 06 Jul, 2015 | US9101660 |
| Issue Fee Payment Verified Critical | 01 Jul, 2015 | US9101660 |
FDA has granted several exclusivities to Actoplus Met. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Actoplus Met, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Actoplus Met.
Exclusivity Information
Actoplus Met holds 1 exclusivities. All of its exclusivities have expired in 2015. Details of Actoplus Met's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-116) | May 17, 2015 |
Several oppositions have been filed on Actoplus Met's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Actoplus Met's generic, the next section provides detailed information on ongoing and past EP oppositions related to Actoplus Met patents.
Actoplus Met's Oppositions Filed in EPO
Actoplus Met has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jul 02, 2014, by Dr Klusmann Peter. This opposition was filed on patent number EP03751344A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP03751344A | Jul, 2014 | Generics [UK] Limited | Patent maintained as amended |
| EP03751344A | Jul, 2014 | Dr Klusmann Peter | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Actoplus Met is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Actoplus Met's family patents as well as insights into ongoing legal events on those patents.
Actoplus Met's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Actoplus Met's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Feb 03, 2029 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Actoplus Met Generic API suppliers:
Metformin Hydrochloride; Pioglitazone Hydrochloride is the generic name for the brand Actoplus Met. 6 different companies have already filed for the generic of Actoplus Met, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Actoplus Met's generic
Alternative Brands for Actoplus Met
Actoplus Met which is used for improving glycemic control in patients with type 2 diabetes already on a combination of pioglitazone and metformin or a thiazolidinedione (TZD) and metformin., has several other brand drugs using the same active ingredient (Metformin Hydrochloride; Pioglitazone Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Takeda Pharms Usa |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metformin Hydrochloride; Pioglitazone Hydrochloride, Actoplus Met's active ingredient. Check the complete list of approved generic manufacturers for Actoplus Met
About Actoplus Met
Actoplus Met is a drug owned by Takeda Pharmaceuticals Usa Inc. It is used for improving glycemic control in patients with type 2 diabetes already on a combination of pioglitazone and metformin or a thiazolidinedione (TZD) and metformin. Actoplus Met uses Metformin Hydrochloride; Pioglitazone Hydrochloride as an active ingredient. Actoplus Met was launched by Takeda Pharms Usa in 2005.
Approval Date:
Actoplus Met was approved by FDA for market use on 29 August, 2005.
Active Ingredient:
Actoplus Met uses Metformin Hydrochloride; Pioglitazone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Metformin Hydrochloride; Pioglitazone Hydrochloride ingredient
Treatment:
Actoplus Met is used for improving glycemic control in patients with type 2 diabetes already on a combination of pioglitazone and metformin or a thiazolidinedione (TZD) and metformin.
Dosage:
Actoplus Met is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 850MG;EQ 15MG BASE | TABLET | Prescription | ORAL |
| 500MG;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |